Construction and Preclinical Evaluation of a


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
01 06 2020
Historique:
pubmed: 2 5 2020
medline: 8 6 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Mesothelin is a molecular biomarker of many types of solid cancers, which may represent a highly promising new target in the development of cancer-targeted diagnostic agents. A human anti-mesothelin antibody with a low molecular weight, ET210sc, was applied; this antibody has potent affinity and can penetrate tissue quickly and stably without causing immunoreactions. We developed a new

Identifiants

pubmed: 32356995
doi: 10.1021/acs.molpharmaceut.9b01281
doi:

Substances chimiques

GPI-Linked Proteins 0
Iodine Isotopes 0
Msln protein, mouse 0
Mesothelin J27WDC343N

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1875-1883

Auteurs

Xudong Wang (X)

State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China.

Feng Wang (F)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Jintao Han (J)

State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China.

Zhi Yang (Z)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Hua Zhu (H)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Gen Yang (G)

State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH